Skip to main content

Advertising Disclaimer »

Main menu

  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers
  • Other Publications
    • American Academy of Pediatrics

User menu

  • Log in
  • My Cart

Search

  • Advanced search
American Academy of Pediatrics

AAP Gateway

Advanced Search

AAP Logo

  • Log in
  • My Cart
  • Journals
    • Pediatrics
    • Hospital Pediatrics
    • Pediatrics in Review
    • NeoReviews
    • AAP Grand Rounds
    • AAP News
  • Authors/Reviewers
    • Submit Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Open Access
    • Editorial Policies
  • Content
    • Current Issue
    • Online First
    • Archive
    • Blogs
    • Topic/Program Collections
    • AAP Meeting Abstracts
  • Pediatric Collections
    • COVID-19
    • Racism and Its Effects on Pediatric Health
    • More Collections...
  • AAP Policy
  • Supplements
  • Multimedia
    • Video Abstracts
    • Pediatrics On Call Podcast
  • Subscribe
  • Alerts
  • Careers

Discover Pediatric Collections on COVID-19 and Racism and Its Effects on Pediatric Health

American Academy of Pediatrics
Special Article

Overdiagnosis: How Our Compulsion for Diagnosis May Be Harming Children

Eric R. Coon, Ricardo A. Quinonez, Virginia A. Moyer and Alan R. Schroeder
Pediatrics November 2014, 134 (5) 1013-1023; DOI: https://doi.org/10.1542/peds.2014-1778
Eric R. Coon
aDivision of Inpatient Medicine, University of Utah School of Medicine, Primary Children’s Hospital, Salt Lake City, Utah;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ricardo A. Quinonez
bBaylor College of Medicine, San Antonio Children’s Hospital, San Antonio, Texas;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Virginia A. Moyer
cAmerican Board of Pediatrics, Maintenance of Certification and Quality, Chapel Hill, North Carolina; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan R. Schroeder
dDepartment of Pediatrics, Santa Clara Valley Medical Center, San Jose, California
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • Comments
Loading
Download PDF

Abstract

Overdiagnosis occurs when a true abnormality is discovered, but detection of that abnormality does not benefit the patient. It should be distinguished from misdiagnosis, in which the diagnosis is inaccurate, and it is not synonymous with overtreatment or overuse, in which excess medication or procedures are provided to patients for both correct and incorrect diagnoses. Overdiagnosis for adult conditions has gained a great deal of recognition over the last few years, led by realizations that certain screening initiatives, such as those for breast and prostate cancer, may be harming the very people they were designed to protect. In the fall of 2014, the second international Preventing Overdiagnosis Conference will be held, and the British Medical Journal will produce an overdiagnosis-themed journal issue. However, overdiagnosis in children has been less well described. This special article seeks to raise awareness of the possibility of overdiagnosis in pediatrics, suggesting that overdiagnosis may affect commonly diagnosed conditions such as attention-deficit/hyperactivity disorder, bacteremia, food allergy, hyperbilirubinemia, obstructive sleep apnea, and urinary tract infection. Through these and other examples, we discuss why overdiagnosis occurs and how it may be harming children. Additionally, we consider research and education strategies, with the goal to better elucidate pediatric overdiagnosis and mitigate its influence.

  • medical education
  • public health
  • Abbreviation:
    ADHD —
    attention-deficit/hyperactivity disorder
  • Overdiagnosis is defined as the identification of an abnormality where detection will not benefit the patient. Unlike misdiagnosis, the finding is accurate; the condition detected may be precisely the condition that was meant to be detected (a true-positive). The notion that an accurate diagnosis could be anything but beneficial runs counter to the conventional wisdom that the more that is known about a patient, the better. Unfortunately, not only do overdiagnosed patients fail to benefit from their diagnosis, they may also be harmed.

    Consider the following common clinical scenarios. An 8-year-old boy with tonsillar hypertrophy on examination and polysomnography consistent with obstructive sleep apnea undergoes an adenotonsillectomy. A 4 year-old girl with a head injury, 2 episodes of vomiting, and a normal physical examination undergoes a head CT scan, which shows a small subdural hematoma, for which she is admitted to the PICU. A 3-month-old girl with bronchiolitis seen in an emergency department has an oxygen saturation of 94% at triage but desaturates to 88% while asleep on continuous pulse oximetry, prompting hospital admission. In each case, the diagnoses were accurate; the diagnostic tests detected precisely what they were intended to detect. Providers may disagree on the optimal treatment approaches for these diagnosed children, but the focus of this article is not mistreatment or overtreatment but rather the incipient event of diagnosis. Did these 3 children benefit from their accurate diagnoses?

    For an individual patient, determining whether a diagnosis is beneficial can be a nearly impossible task, just as it is often difficult to tell how much benefit an individual derives from treatment; one can never know with certainty what would have happened if the diagnosis had not been made or the treatment not given. However, just as it is possible to evaluate the likelihood of benefit from treatments across populations, it is possible to know the likelihood of benefit from diagnostic testing.

    Research Methods to Investigate Overdiagnosis

    The following experimental designs have been used to detect overdiagnosis.

    Randomized Trials of Screening Tests

    The most convincing examples of overdiagnosis come from randomized trials of cancer screening tests. If patients randomly assigned to screening experience more diagnosis of disease but do not experience net benefit (generally measured in terms of overall mortality) compared with those randomly assigned to no screening or less screening, overdiagnosis exists. For example, in the recent Canadian trial of screening mammography involving almost 90 000 women, breast cancer diagnosis was unsurprisingly more common in women randomly assigned to receive annual mammography than in women assigned to no mammography.1 However, over the next 25 years all-cause and breast cancer–specific mortality were equivalent in both groups. The authors estimated that 1 overdiagnosed breast cancer occurs for every 424 women who undergo screening mammography. Mammography was successful in detecting breast cancer but did not save lives. Randomized trials were similarly used to demonstrate overdiagnosis of neuroblastoma in young children with implementation of universal urine screening (Table 1). A German trial found unchanged mortality rates from neuroblastoma after widespread screening with urinary catecholamines at 1 year of age and estimated that 62% of neuroblastoma cases identified were overdiagnosed.2,3 A Canadian trial of universal screening for neuroblastoma yielded similar results.4 However, it should be noted that randomized trial designs are often limited by a commitment to internal validity and efficacy, which limits generalizability. Testing or screening interventions may show an effect under idealized trial conditions, but post hoc naturalistic studies may be better equipped to evaluate their effectiveness in real-world conditions.

    View this table:
    • View inline
    • View popup
    TABLE 1

    Examples of Possible Overdiagnosis in Pediatrics

    The Natural Experiment: Delayed or Missed Diagnoses Without Patient Harm

    Diagnoses made after a patient has overcome the abnormality or remained asymptomatic over a lifetime, despite the absence of detection and medical intervention, suggest overdiagnosis. For example, nearly 10% of men in their 20s and >80% of men in their 70s have prostate cancer discovered incidentally on autopsy after they die from an accident, yet only 3% of men die of prostate cancer.5,6 In other words, although many men have or will have prostate cancer, most are not overtly harmed by this condition. Indeed, randomized trials of prostate cancer screening have demonstrated increased detection with screening without an improvement in mortality.7,8 In children, studies have identified proportions of missed and untreated diagnoses of bacteremia,9 urinary tract infection (UTI),10 and medium-chain acyl-coenzyme A dehydrogenase deficiency,11 without any harm to the child (Table 1). This study design can be confounded by prognostic factors, in that missed diagnoses may be systematically different (ie, milder or more indolent) compared with conditions that reached detection.

    Increasing Disease Incidence but Unchanging Morbidity or Mortality

    An increasing incidence of diagnosis of a specific disease should always trigger suspicion of overdiagnosis. When the increase in incidence is accompanied by an unchanging rate of the outcome important to patients (usually mortality), overdiagnosis is a likely explanation. For example, thyroid cancer incidence increased almost two and a half fold from 1973 to 2002, but mortality due to thyroid cancer did not change.12 Analogous pediatric examples include hypoxemia in bronchiolitis and hyperbilirubinemia (Table 1), where increased detection and treatment of both conditions has not decreased mortality.13,14 An alternative explanation could be that a clinically important increase in incidence occurred, but an otherwise higher rate of outcomes important to patients was exactly matched by effective treatment modalities, keeping outcomes constant. This explanation requires both a biologic mechanism to explain a truly increased incidence and evidence of improved treatment outcomes.

    Although it is clear that the most conclusive evidence of overdiagnosis comes from adult trials of cancer screening, it has been suggested that overdiagnosis also affects nonneoplastic, common adult conditions such as hypertension, diabetes, and osteoporosis.15 In these chronic diseases, lowering the threshold values for disease has further increased the risk of overdiagnosis.15 Similarly, overdiagnosis is probably affecting routine conditions in pediatrics. However, although the importance of overdiagnosis as a driver of avoidable and potentially harmful medical care in adult populations has gained prominence recently, through conferences,16 books,15 and dedicated themed journal issues,17 the phenomenon is rarely described in pediatrics.

    Overdiagnosis in Children

    There will almost always be a proportion of patients who benefit from any diagnosis, including the examples we have chosen. In evaluating the importance of overdiagnosis in a condition at the population level, we propose focusing on the frequency of overdiagnoses relative to needed diagnoses, the ratio of potential benefits from needed diagnoses to potential harms from overdiagnoses, and the amount of resource utilization resulting from overdiagnosis. Thus, the examples in Table 1 feature diagnoses with unclear or infrequent opportunity for benefit, the possibility for harm, or high resource utilization.

    For example, universal or nearly universal bilirubin screening is common in the United States, intended to decrease infants’ risk of kernicterus, a rare but devastating neurologic condition. However, the number of infants who must be treated with phototherapy to prevent 1 infant from needing exchange transfusion is high,18 meaning that most infants with hyperbilirubinemia do not benefit from diagnosis and treatment. The number needed to treat for the more important outcome, kernicterus, is probably much larger. Unfortunately, as concluded by the US Preventive Services Task Force19 in 2009, evidence to support the efficacy of screening and treatment to reduce the risk of kernicterus is inadequate. Nevertheless, 10 to 80 in 1000 term and preterm infants are treated for hyperbilirubinemia in the United States, at a cost of $150 million per year for the healthy term cohort.20 Because kernicterus is a devastating and potentially lethal condition, overdiagnosis and overtreatment of hyperbilirubinemia have been accepted as a reasonable tradeoff. However, the potential for harm from hospitalization and treatment of hyperbilirubinemia has not been adequately researched, and recent findings of a possible association between phototherapy and childhood leukemia may affect the risk/benefit analysis.21,22

    How Is Overdiagnosis Harmful?

    Medical tests are more accessible, rapid, and frequently consumed than ever before. Discussions between patients and providers tend to focus on the potential benefits of testing, with less regard for potential harms.23 Yet a single test can give rise to a cascade of events, many of which have the potential to harm.24 We use a recently published taxonomy of 4 harm domains to frame the harms of overdiagnosis in pediatrics: physical effects, psychological effects, financial strain, and opportunity cost.25

    Physical Effects

    The physical effects of testing and interventions motivated by overdiagnoses are the most visible harms of unnecessary detection of an abnormality. Until recently, the standard of care for small, localized adrenal tumors in infants, including those overdiagnosed by neuroblastoma screening, was surgical resection, the mortality of which is 2% or higher.26 For young infants with fever, the detection of bacteremia leads to prolongation of antibiotic therapy,27 often via a peripherally inserted central catheter, for which the complication rate necessitating line removal in children <1 year of age is 48%.28 The gold standard diagnostic test for aspiration, a videofluoroscopic swallow study, exposes subjects to radiation, and an aspiration diagnosis often results in an intervention, ranging from thickening feeds to surgery for gastric tubes and Nissen fundoplications.

    Psychological Effects

    Subtle but potentially common byproducts of overdiagnosis are psychological effects, because all diagnoses, whether beneficial to the patient or not, change the perception of the child for the child, his or her caregivers, and society. Fundamentally, diagnoses connote abnormality, something to be remedied. One recent study found that parents given a hypothetical clinical scenario of a child with a gastroesophageal reflux disease label were more likely to believe the child would benefit from medication than parents given the same scenario without a gastroesophageal reflux disease label, a belief that persisted even when parents were told that the medications were probably ineffective.29

    Parental belief in their child’s vulnerability after illness, despite full recovery, was first described in 1964.30 Unfortunately, the debilitating effects of the “vulnerable child syndrome” require only that a diagnosis is made, regardless of a child’s ability to benefit from the diagnosis. Forty percent of junior high school children with a history of an innocent heart murmur or other cardiac nondisease in 1 study suffered physical and psychological restriction after their diagnosis.31 In another study, parents of children with feeding and crying problems in infancy necessitating a change in formula were more likely to perceive their child as vulnerable >3 years later, despite being no more likely to report allergies, asthma, or eczema for their child.32 Finally, parents of infants with jaundice or phototherapy exposure are more likely to seek medical attention for their child well after jaundice resolution,33 perceive subsequent illnesses as moderate or severe, and fear leaving their baby with any other caregiver.34

    Diagnoses also affect how children are treated by society. Approximately one-third of children with food allergy (a diagnosis now given to ∼8% of children) suffer from allergy-related bullying and an associated lower quality of life.35,36 The widespread bullying of children with this diagnosis has prompted the “It’s Not a Joke” campaign, highlighting the emotional toll of food allergy bullying.37

    Financial Strain

    Overdiagnosis is also harmful because of the resultant financial costs. Unnecessary and wasteful care are estimated to constitute 21% to 47% of all expenditures, which probably ignores the contribution of overdiagnosis given that accurate diagnoses, regardless of their benefit to the patient, are assumed to be necessary.38 Providing oxygen to children with bronchiolitis, stimulants to students with attention or hyperactivity problems, and phototherapy to infants with elevated bilirubin values are unlikely to be included in waste estimates, despite the fact that in some cases these interventions are not beneficial. The annual US health care costs for each of these conditions are $543 million,39 $1.6 billion,40 and $150 million,20 respectively.

    Opportunity Cost

    Finally, consideration must be given to the opportunity cost of overdiagnosis, the possibility that needed medical care is not provided because of unnecessary diagnoses, their subsequent interventions, and the psychological and financial burdens they impose. Unfortunately, this is an almost completely unstudied harm of overdiagnosis. The value of patient and family time and the quantity of their financial resources consumed by care related to overdiagnosis are unquantified. The attention and resources that providers could divert to patients who stand to benefit from diagnoses and treatments, were they not consumed by the overdiagnosed, are also unquantified.

    What Is Driving Overdiagnosis?

    Drivers of excessive care are poorly quantified in health care in general, and we are aware of no research quantifying the factors that motivate pediatricians to test or treat. Drawing on the limited available literature from adult medicine, we propose several candidate drivers of overdiagnosis in pediatrics.

    Physician Factors

    Overdiagnosis is rarely addressed in the pediatric literature, and some pediatric providers may not be aware that the detection of abnormalities could be harmful. If a diagnostic test discovers the condition it was meant to discover, how could it have been unnecessary or even harmful? A head CT scan revealing a small bleed or a skull fracture might leave a practitioner feeling validated by his or her decision to obtain the CT scan, even though detection of these abnormalities is unlikely to change management in a way that benefits the patient. If physicians are not aware of the potential harms of overdiagnosis, patients and families cannot be expected to appreciate them either. A survey of adult medicine providers found that their understanding of cancer screening statistics, including overdiagnosis, was poor. Almost half of those surveyed believed that finding more cancer cases in screened as opposed to unscreened populations proved that screening saved lives.41 Unfortunately, similar knowledge assessments have not been performed in pediatrics.

    Intolerance of uncertainty can be a powerful motivator for diagnostic testing.42–44 Providers may be troubled by not having an answer to explain a patient’s complaint and respond to this uncertainty by relying on diagnostic tests or expert consultation. Provider perceptions that families want an answer, that testing expresses caring, and that watchful waiting ignores patient needs may propagate this behavior. For example, in a study investigating decisions to obtain head CT scans in children with minor blunt head trauma, providers acknowledged the influence of parental anxiety or request on their decision to order more CT scans. Interestingly, white non-Hispanic children were more likely to undergo unnecessary cranial CT scanning than their minority counterparts.45

    The culture of medical education is an early impetus for training providers to find comfort in commission and fear in uncertainty.46 Problem-based learning strategies in medical school encourage a shotgun approach, which tends to reward unusual diagnoses and contributes to overtesting and overdiagnosis.47–49 An emphasis on avoiding omission errors in case report conferences and morbidity and mortality conferences may strengthen these tendencies. Given this milieu, the production of providers eager for diagnosis, but unsighted of its possibility to harm, is only natural.

    Finally, fear of litigation may motivate unnecessary testing, exposing patients to unnecessary diagnoses. Indeed, errors of omission (a patient is harmed because a necessary test or treatment was not provided) are more frequently punished by litigation than errors of commission (a patient is harmed because an unnecessary test or treatment was provided).50 However, although providers often cite defensive medicine as a stimulus for unnecessary testing and care,51,52 reforms to lessen provider liability do not necessarily change their behavior.53

    System Incentives

    External systemic forces may incentivize testing and diagnosis. Fee-for-service reimbursement, a target for reform, financially rewards providers for providing more, and potentially excessive, care. Supply-sensitive care, where higher capacity in the form of hospital beds and imaging modalities drives medical utilization, inevitably uncovers patient abnormalities.54 Proposed pediatric quality indicators tend to encourage greater testing and treatment. In one evaluation, only 5 in 242 proposed pediatric ambulatory indicators focused on problems of overuse (compared with 225 in 242 for underuse),55 whereas none of the 62 pediatric emergency department indicators in a separate assessment evaluated unnecessary tests.56 In addition, physicians more readily improve on quality indicators aimed at underuse as opposed to overuse.57 Finally, time constraints and loss of continuity of care lead to a substitution of testing for thorough review of records and patient assessment.58,59

    Industry Influence

    Industry interests contribute to overdiagnosis by lobbying for widened diagnostic boundaries and using the media to generate demand for diagnosis, both of which create more patients and more profit.60 For example, lowering the definition of hypercholesterolemia in adults from 240 to 200 mg/dL, a 2002 recommendation made by an expert panel where 8 of 9 panelists had financial conflicts of interest, created >42 million new diagnoses.61,62 Such conflicts of interest in defining disease are not unusual. In one study, 75% of members of panels responsible for defining the most common diseases in the United States had ties to industry that stood to benefit from expanded definitions.63 The 2012 attention-deficit/hyperactivity disorder (ADHD) guideline panel included 9 members, 5 of whom had industry ties to manufacturers of widely used medications for ADHD.63 Based on this committee’s recommendations, the definition of ADHD was broadened to include children 4 to 18 years old (previously 6–12 years old).64 Although it is unclear how many new diagnoses of ADHD this expansion created, diagnostic creep has resulted in the prescription of stimulants to >10 000 toddlers aged 2 and 3 years old.65 Similar to concerns generated by the extension of the diagnosis of depressive disorder to include bereavement, the ADHD expansion risks medicalizing variations of normal human behavior.66

    Patients are also influenced by industry. Pharmaceutical companies spent $4.5 billion on direct-to-consumer marketing in 2009.67 Advertisements capitalize on our fear of undiagnosed disease and urge us to see our doctor for testing. Industry also reaches patients through patient advocacy groups. Once considered unbiased, third-party advocacy groups are often used to deliver the same message. A random sample of US patient groups found that 80% received industry funding.68 The National Alliance on Mental Illness, a mental health advocacy organization, received $23 million, or approximately three-quarters of its donations, from drug makers between 2006 and 2008.69

    Public Psyche

    Belief in scientific advance and a technological imperative, a confidence that the use of technology to detect disease is always beneficial, also drive overdiagnosis. A positive feedback loop of testing ensues, in which the test results, independent of the actual value (positive, negative, false-positive, or false-negative), confirm for patients that they should have been tested and make them more likely to seek additional testing.15 In a survey of adults, 98% of those who had experienced a false-positive test were glad they had the initial screening test, and 73% of all respondents would forgo $1000 in cash for a total body CT scan.70 Two buttresses of public enthusiasm for screening are lead time and length bias, which mistakenly bolster the argument for testing by erroneously overestimating prevalence and improved outcomes. Lead time bias occurs when diagnoses are identified earlier than they would be discovered clinically, falsely appearing to prolong survival, and length bias occurs when screening identifies disproportionately milder diagnoses.71

    The Way Forward

    A research agenda aimed at evaluating the harms and benefits of individual pediatric diagnoses and the frequency of overdiagnosis is needed. Of the examples presented here, the only conclusive evidence of pediatric overdiagnosis is for neuroblastoma screening.2–4 Currently, most studies of diagnostic tests report on test accuracy rather than evaluating whether the test results led to important outcomes that benefited patients. The 3 research methods previously outlined (randomized trials, natural experiments, and comparison of incidence versus outcomes) provide reasonable starting points for studying the possibility of overdiagnosis for a particular abnormality. Additionally, practice variation may be an important beacon for overdiagnosis. Conditions for which testing and diagnostic variation exist, but important patient outcomes do not differ, would suggest overdiagnosis.

    Because providers may be reluctant to accept evidence that is counter to their customary practice or experience, investigations delineating pediatric overdiagnosis ultimately must be augmented by advocacy and awareness efforts. The campaigns in Table 2 have each made strong contributions to this objective. Choosing Wisely is an example of dissemination and implementation of measures that aid providers in decreasing practice variation and unnecessary diagnostic testing, which may reduce the risk of overdiagnosis. Specifically, the majority of the pediatric Choosing Wisely initiatives decrease opportunities for overdiagnosis, with recommendations that limit the use of CT scans, MRI, chest radiographs, apnea monitors, food allergy screening, and continuous pulse oximetry.72,73 In general, guidelines that endorse testing can address the harms of overdiagnosis and support strong recommendations for testing with evidence that important outcomes for children are improved by diagnosis. Use of the US Preventive Services Task Force analytic framework, which considers both harms and benefits and clearly delineates pertinent outcomes, would help guideline panels in this endeavor.74

    View this table:
    • View inline
    • View popup
    TABLE 2

    Overdiagnosis Awareness and Mitigation Resources

    Despite efforts made by the organizations listed in Table 2, there remains a large proportion of underinformed patients: Only 9.5% of adults with high exposure to cancer screening programs reported being advised by their physician about the risk of overdiagnosis or overtreatment from screening.75 Future pediatric research can evaluate the impact on patient decision-making when patients are exposed to farther-reaching impacts of a diagnosis. In Table 3, we list several common clinical scenarios where diagnostic tests are performed and provide examples of both proximate and long-term perspectives on why the test might be indicated. The proximate perspective addresses the immediate rationale for a diagnostic test, whereas the long-term perspective assesses possible diagnostic results and subsequent interventions. Both perspectives are important, but discussions about less immediate diagnostic corollaries, in particular, will help patients and providers frame testing decisions within the context of potential overdiagnosis. Although it is unclear how this type of shared decision-making would affect diagnostic testing in children, examples from adult medicine reveal that many patients opt out of tests when provided comprehensive evidence on risks and benefits.76

    View this table:
    • View inline
    • View popup
    TABLE 3

    “Why Are We Doing This test?”: Proximate Versus Long-Term Implications for Diagnostic Testing

    Finally, the incorporation of overdiagnosis into medical education curricula is critical. Students may be guided to produce carefully crafted differentials and workups that are probabilistic rather than “possibilistic.”77 Differential-generating teaching sessions can acknowledge the risk of overdiagnosis, and morbidity and mortality conferences can expand to include cases of harms caused by overdiagnosis. The Do No Harm Project, vignettes produced by University of Colorado internal medicine residents illustrating harms from medical overuse, can serve as a model in the development of pediatric-specific curricula to directly address overdiagnosis.78 Perhaps most importantly, medical education can discourage black-and-white thinking, instead nurturing critical thinking and comfort with uncertainty. If symptoms are not severe, a stepped approach can be undertaken to reduce the risk of overdiagnosis. This method begins with normalizing problems, if appropriate, and pursuing a period of watchful waiting.79 If resolution or an acceptable level of improvement does not occur with watchful waiting, minimal interventions, with the potential for diagnosis, are used. Such a patient approach is important, because the risk of overdiagnosis is greatest for the child with no symptoms or a few nonspecific symptoms; the milder an abnormality, the less potential for benefit.15 If the magnitude of hypothetical benefit is small for pursuing a diagnosis and the possibility of harm exists, perhaps the child and family are better off avoiding diagnostic exposure.

    Conclusions

    Substantial proportions of children may not benefit from commonly pursued pediatric diagnoses. In some cases, overdiagnosis is necessary to ensure larger gains for the children who do benefit from the diagnosis. However, for many diagnostic tests, the ratio of benefit to harm resulting from the diagnosis is incompletely understood. Patient, physician, investigator, and society-wide attention to this complex benefit assessment will help ensure that we, first, do no harm.

    Acknowledgments

    The authors thank Christopher G. Maloney, MD, PhD, and Thomas B. Newman, MD, MPH, for their thoughtful review of this article.

    Footnotes

      • Accepted August 20, 2014.
    • Address correspondence to Eric R. Coon, MD, Department of Pediatrics, Division of Inpatient Medicine, University of Utah School of Medicine, Primary Children’s Hospital, 100 North Mario Capecchi Dr, Salt Lake City, UT 84113. E-mail: eric.coon{at}hsc.utah.edu
    • Dr Coon participated in conception and design, drafted the initial manuscript, and critically reviewed and revised the manuscript; Drs Quinonez, Moyer, and Schroeder participated in conception and design and critically reviewed and revised the manuscript; and all authors approved the final manuscript as submitted.

    • FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

    • FUNDING: No external funding.

    • POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.

    References

    1. ↵
      1. Miller AB,
      2. Wall C,
      3. Baines CJ,
      4. Sun P,
      5. To T,
      6. Narod SA
      . Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial. BMJ. 2014;348:g366pmid:24519768
      OpenUrlAbstract/FREE Full Text
    2. ↵
      1. Schilling FH,
      2. Spix C,
      3. Berthold F,
      4. et al
      . Neuroblastoma screening at one year of age. N Engl J Med. 2002;346(14):1047–1053pmid:11932471
      OpenUrlCrossRefPubMed
    3. ↵
      1. Spix C,
      2. Michaelis J,
      3. Berthold F,
      4. Erttmann R,
      5. Sander J,
      6. Schilling FH
      . Lead-time and overdiagnosis estimation in neuroblastoma screening. Stat Med. 2003;22(18):2877–2892pmid:12953286
      OpenUrlCrossRefPubMed
    4. ↵
      1. Woods WG,
      2. Gao RN,
      3. Shuster JJ,
      4. et al
      . Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346(14):1041–1046pmid:11932470
      OpenUrlCrossRefPubMed
    5. ↵
      National Cancer Institute. Surveillance, epidemiology, and end results program. Available at: http://seer.cancer.gov
    6. ↵
      1. Sakr WA,
      2. Grignon DJ,
      3. Haas GP,
      4. Heilbrun LK,
      5. Pontes JE,
      6. Crissman JD
      . Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol. 1996;30(2):138–144pmid:8875194
      OpenUrlPubMed
    7. ↵
      1. Ilic D,
      2. Neuberger MM,
      3. Djulbegovic M,
      4. Dahm P
      . Screening for prostate cancer. Cochrane Database Syst Rev. 2013;1:CD004720pmid:23440794
      OpenUrlPubMed
    8. ↵
      1. Andriole GL,
      2. Crawford ED,
      3. Grubb RL III,
      4. et al.,
      5. PLCO Project Team
      . Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360(13):1310–1319pmid:19297565
      OpenUrlCrossRefPubMed
    9. ↵
      1. Jaffe DM,
      2. Tanz RR,
      3. Davis AT,
      4. Henretig F,
      5. Fleisher G
      . Antibiotic administration to treat possible occult bacteremia in febrile children. N Engl J Med. 1987;317(19):1175–1180pmid:3309658
      OpenUrlCrossRefPubMed
    10. ↵
      1. Newman TB,
      2. Bernzweig JA,
      3. Takayama JI,
      4. Finch SA,
      5. Wasserman RC,
      6. Pantell RH
      . Urine testing and urinary tract infections in febrile infants seen in office settings: the Pediatric Research in Office Settings’ Febrile Infant Study. Arch Pediatr Adolesc Med. 2002;156(1):44–54pmid:11772190
      OpenUrlCrossRefPubMed
    11. ↵
      1. Waisbren SE,
      2. Albers S,
      3. Amato S,
      4. et al
      . Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA. 2003;290(19):2564–2572pmid:14625333
      OpenUrlCrossRefPubMed
    12. ↵
      1. Davies L,
      2. Welch HG
      . Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006;295(18):2164–2167pmid:16684987
      OpenUrlCrossRefPubMed
    13. ↵
      1. Shay DK,
      2. Holman RC,
      3. Roosevelt GE,
      4. Clarke MJ,
      5. Anderson LJ
      . Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis. 2001;183(1):16–22pmid:11076709
      OpenUrlAbstract/FREE Full Text
    14. ↵
      1. Brooks JC,
      2. Fisher-Owens SA,
      3. Wu YW,
      4. Strauss DJ,
      5. Newman TB
      . Evidence suggests there was not a “resurgence” of kernicterus in the 1990s. Pediatrics. 2011;127(4):672–679pmid:21444599
      OpenUrlAbstract/FREE Full Text
    15. ↵
      1. Welch HG,
      2. Schwartz L,
      3. Woloshin S
      . Overdiagnosed: Making People Sick in the Pursuit of Health. Boston, MA: Beacon Press; 2011
    16. ↵
      Preventing Overdiagnosis Conference. Available at: www.preventingoverdiagnosis.net/
    17. ↵
      1. Moynihan R,
      2. Glasziou P,
      3. Woloshin S,
      4. Schwartz L,
      5. Santa J,
      6. Godlee F
      . Winding back the harms of too much medicine. BMJ. 2013;346:f1271pmid:23444422
      OpenUrlFREE Full Text
    18. ↵
      1. Newman TB,
      2. Kuzniewicz MW,
      3. Liljestrand P,
      4. Wi S,
      5. McCulloch C,
      6. Escobar GJ
      . Numbers needed to treat with phototherapy according to American Academy of Pediatrics guidelines. Pediatrics. 2009;123(5):1352–1359pmid:19403502
      OpenUrlAbstract/FREE Full Text
    19. ↵
      1. US Preventive Services Task Force
      . Screening of infants for hyperbilirubinemia to prevent chronic bilirubin encephalopathy: US Preventive Services Task Force recommendation statement. Pediatrics. 2009;124(4):1172–1177pmid:19786451
      OpenUrlAbstract/FREE Full Text
    20. ↵
      1. Suresh GK,
      2. Clark RE
      . Cost-effectiveness of strategies that are intended to prevent kernicterus in newborn infants. Pediatrics. 2004;114(4):917–924pmid:15466085
      OpenUrlAbstract/FREE Full Text
    21. ↵
      1. Podvin D,
      2. Kuehn CM,
      3. Mueller BA,
      4. Williams M
      . Maternal and birth characteristics in relation to childhood leukaemia. Paediatr Perinat Epidemiol. 2006;20(4):312–322pmid:16879503
      OpenUrlCrossRefPubMed
    22. ↵
      Wickremasinghe AC, Grimes B, McCulloch CE, Newman TB. Association between neonatal phototherapy and admissions for infantile cancer. Paper presented at: Pediatric Academic Societies, platform presentation; 2014; Vancouver, BC
    23. ↵
      1. Hoffman RM,
      2. Lewis CL,
      3. Pignone MP,
      4. et al.
      Decision-making processes for breast, colorectal, and prostate cancer screening: the DECISIONS survey. Med Decis Making. 2010;30(5 suppl):53s–64s
      OpenUrlCrossRefPubMed
    24. ↵
      1. Mold JW,
      2. Stein HF
      . The cascade effect in the clinical care of patients. N Engl J Med. 1986;314(8):512–514pmid:24322781
      OpenUrlCrossRefPubMed
    25. ↵
      1. Harris RP,
      2. Sheridan SL,
      3. Lewis CL,
      4. et al
      . The harms of screening: a proposed taxonomy and application to lung cancer screening. JAMA Intern Med. 2014;174(2):281–285pmid:24322781
      OpenUrlCrossRefPubMed
    26. ↵
      1. Nuchtern JG,
      2. London WB,
      3. Barnewolt CE,
      4. et al
      . A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg. 2012;256(4):573–580pmid:22964741
      OpenUrlCrossRefPubMed
    27. ↵
      1. Roman HK,
      2. Chang PW,
      3. Schroeder AR
      . Diagnosis and management of bacteremic urinary tract infection in infants. Hosp Pediatr. In press
    28. ↵
      1. Jumani K,
      2. Advani S,
      3. Reich NG,
      4. Gosey L,
      5. Milstone AM
      . Risk factors for peripherally inserted central venous catheter complications in children. JAMA Pediatr. 2013;167(5):429–435pmid:23549677
      OpenUrlCrossRefPubMed
    29. ↵
      1. Scherer LD,
      2. Zikmund-Fisher BJ,
      3. Fagerlin A,
      4. Tarini BA
      . Influence of “GERD” label on parents’ decision to medicate infants. Pediatrics. 2013;131(5):839–845pmid:23545371
      OpenUrlAbstract/FREE Full Text
    30. ↵
      1. Green M,
      2. Solnit AJ
      . Reactions to the threatened loss of a child: a vulnerable child syndrome. Pediatric management of the dying child, part III. Pediatrics. 1964;34:58–66pmid:14181986
      OpenUrlAbstract/FREE Full Text
    31. ↵
      1. Bergman AB,
      2. Stamm SJ
      . The morbidity of cardiac nondisease in schoolchildren. N Engl J Med. 1967;276(18):1008–1013pmid:6022469
      OpenUrlCrossRefPubMed
    32. ↵
      1. Forsyth BW,
      2. Canny PF
      . Perceptions of vulnerability 3 1/2 years after problems of feeding and crying behavior in early infancy. Pediatrics. 1991;88(4):757–763pmid:1896279
      OpenUrlAbstract/FREE Full Text
    33. ↵
      1. Usatin D,
      2. Liljestrand P,
      3. Kuzniewicz MW,
      4. Escobar GJ,
      5. Newman TB
      . Effect of neonatal jaundice and phototherapy on the frequency of first-year outpatient visits. Pediatrics. 2010;125(4):729–734pmid:20231183
      OpenUrlAbstract/FREE Full Text
    34. ↵
      1. Kemper K,
      2. Forsyth B,
      3. McCarthy P
      . Jaundice, terminating breast-feeding, and the vulnerable child. Pediatrics. 1989;84(5):773–778pmid:2797972
      OpenUrlAbstract/FREE Full Text
    35. ↵
      1. Shemesh E,
      2. Annunziato RA,
      3. Ambrose MA,
      4. et al
      . Child and parental reports of bullying in a consecutive sample of children with food allergy. Pediatrics. 2013;131(1). Available at: www.pediatrics.org/cgi/content/full/131/1/e10pmid:23266926
      OpenUrlAbstract/FREE Full Text
    36. ↵
      1. Gupta RS,
      2. Springston EE,
      3. Warrier MR,
      4. et al
      . The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128(1). Available at: www.pediatrics.org/cgi/content/full/128/1/e9pmid:21690110
      OpenUrlAbstract/FREE Full Text
    37. ↵
      Food Allergy Research & Education. Food allergy bullying: it’s not a joke. 2014; Available at: www.foodallergy.org/its-not-a-joke#.Ur2nRPRDt8E
    38. ↵
      1. Berwick DM,
      2. Hackbarth AD
      . Eliminating waste in US health care. JAMA. 2012;307(14):1513–1516pmid:22419800
      OpenUrlCrossRefPubMed
    39. ↵
      1. Pelletier AJ,
      2. Mansbach JM,
      3. Camargo CA Jr
      . Direct medical costs of bronchiolitis hospitalizations in the United States. Pediatrics. 2006;118(6):2418–2423pmid:17142527
      OpenUrlAbstract/FREE Full Text
    40. ↵
      1. Birnbaum HG,
      2. Kessler RC,
      3. Lowe SW,
      4. et al
      . Costs of attention deficit–hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000. Curr Med Res Opin. 2005;21(2):195–206pmid:15801990
      OpenUrlCrossRefPubMed
    41. ↵
      1. Wegwarth O,
      2. Schwartz LM,
      3. Woloshin S,
      4. Gaissmaier W,
      5. Gigerenzer G
      . Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. Ann Intern Med. 2012;156(5):340–349pmid:22393129
      OpenUrlCrossRefPubMed
    42. ↵
      1. Merrill JM,
      2. Lorimor RJ,
      3. Thornby JI,
      4. Vallbona C
      . Reliance on high technology among senior medical students. Am J Med Sci. 1998;315(1):35–39pmid:9427573
      OpenUrlCrossRefPubMed
      1. van der Weijden T,
      2. van Bokhoven MA,
      3. Dinant GJ,
      4. van Hasselt CM,
      5. Grol RP
      . Understanding laboratory testing in diagnostic uncertainty: a qualitative study in general practice. Br J Gen Pract. 2002;52(485):974–980
      OpenUrlAbstract/FREE Full Text
    43. ↵
      1. Lysdahl KB,
      2. Hofmann BM
      . What causes increasing and unnecessary use of radiological investigations? A survey of radiologists’ perceptions. BMC Health Serv Res. 2009;9:155pmid:19723302
      OpenUrlCrossRefPubMed
    44. ↵
      1. Natale JE,
      2. Joseph JG,
      3. Rogers AJ,
      4. et al.,
      5. PECARN (Pediatric Emergency Care Applied Research Network)
      . Cranial computed tomography use among children with minor blunt head trauma: association with race/ethnicity. Arch Pediatr Adolesc Med. 2012;166(8):732–737pmid:22869404
      OpenUrlCrossRefPubMed
    45. ↵
      1. Nevalainen M,
      2. Kuikka L,
      3. Sjoberg L,
      4. Eriksson J,
      5. Pitkala K
      . Tolerance of uncertainty and fears of making mistakes among fifth-year medical students. Fam Med. 2012;44(4):240–246pmid:22481152
      OpenUrlPubMed
    46. ↵
      1. Samadian S,
      2. Farhat A
      . Problem based learning, litigation, and EWTD contribute to too much medicine. BMJ. 2013;347:f4790pmid:23900824
      OpenUrlFREE Full Text
    47. Woodward C, Ferrier B, Goldsmith C, Cohen M. Billing patterns of general practitioners and family physicians in Ontario: a comparison of graduates of McMaster Medical School with graduates of other Ontario medical schools. In: Research in Medical Education: Proceedings of the Annual Conference. Conference on Research in Medical Education. 1988;27:276–281
    48. ↵
      1. Emanuel EJ,
      2. Fuchs VR
      . The perfect storm of overutilization. JAMA. 2008;299(23):2789–2791pmid:18560006
      OpenUrlCrossRefPubMed
    49. ↵
      1. Wallace E,
      2. Lowry J,
      3. Smith SM,
      4. Fahey T
      . The epidemiology of malpractice claims in primary care: a systematic review. BMJ Open. 2013;3(7)pmid:23869100
      OpenUrlPubMed
    50. ↵
      1. Bishop TF,
      2. Federman AD,
      3. Keyhani S
      . Physicians’ views on defensive medicine: a national survey. Arch Intern Med. 2010;170(12):1081–1083pmid:20585077
      OpenUrlCrossRefPubMed
    51. ↵
      1. Sirovich BE,
      2. Woloshin S,
      3. Schwartz LM
      . Too little? Too much? Primary care physicians’ views on US health care: a brief report. Arch Intern Med. 2011;171(17):1582–1585pmid:21949169
      OpenUrlCrossRefPubMed
    52. ↵
      1. Sloan FA,
      2. Shadle JH
      . Is there empirical evidence for “defensive medicine”? A reassessment. J Health Econ. 2009;28(2):481–491pmid:19201500
      OpenUrlCrossRefPubMed
    53. ↵
      The Dartmouth Atlas Project. Supply-sensitive care. January 15, 2007. Available at: www.dartmouthatlas.org/downloads/reports/supply_sensitive.pdf
    54. ↵
      1. Mangione-Smith R,
      2. DeCristofaro AH,
      3. Setodji CM,
      4. et al
      . The quality of ambulatory care delivered to children in the United States. N Engl J Med. 2007;357(15):1515–1523pmid:17928599
      OpenUrlCrossRefPubMed
    55. ↵
      1. Stang AS,
      2. Straus SE,
      3. Crotts J,
      4. Johnson DW,
      5. Guttmann A
      . Quality indicators for high acuity pediatric conditions. Pediatrics. 2013;132(4):752–762pmid:24062374
      OpenUrlAbstract/FREE Full Text
    56. ↵
      1. Kale MS,
      2. Bishop TF,
      3. Federman AD,
      4. Keyhani S
      . Trends in the overuse of ambulatory health care services in the United States. JAMA Intern Med. 2013;173(2):142–148pmid:23266529
      OpenUrlCrossRefPubMed
    57. ↵
      1. Bosanquet D,
      2. Cho J,
      3. Williams N,
      4. Gower D,
      5. Thomas KG,
      6. Lewis M
      . Requesting radiological investigations: do junior doctors know their patients? A cross-sectional survey. JRSM Short Rep. 2013;4(1):3
      OpenUrlAbstract/FREE Full Text
    58. ↵
      1. Rogg JG,
      2. Rubin JT,
      3. Hansen P,
      4. Liu SW
      . The frequency and cost of redundant laboratory testing for transferred ED patients. Am J Emerg Med. 2013;31(7):1121–1123pmid:23702071
      OpenUrlCrossRefPubMed
    59. ↵
      1. Moynihan R,
      2. Henry D
      . The fight against disease mongering: generating knowledge for action. PLoS Med. 2006;3(4):e191pmid:16597180
      OpenUrlCrossRefPubMed
    60. ↵
      1. Schwartz LM,
      2. Woloshin S
      . Changing disease definitions: implications for disease prevalence. Analysis of the Third National Health and Nutrition Examination Survey, 1988–1994. Eff Clin Pract. 1999;2(2):76–85pmid:10538480
      OpenUrlPubMed
    61. ↵
      1. Ricks D,
      2. Rabin R
      . Cholesterol guidelines: drug panelist’s links under fire. Newsday, July 15, 2004
    62. ↵
      1. Moynihan RN,
      2. Cooke GP,
      3. Doust JA,
      4. Bero L,
      5. Hill S,
      6. Glasziou PP
      . Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLoS Med. 2013;10(8):e1001500pmid:23966841
      OpenUrlCrossRefPubMed
    63. ↵
      1. Wolraich M,
      2. Brown L,
      3. Brown RT,
      4. et al.,
      5. Subcommittee on Attention-Deficit/Hyperactivity Disorder,
      6. Steering Committee on Quality Improvement and Management
      . ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128(5):1007–1022pmid:22003063
      OpenUrlAbstract/FREE Full Text
    64. ↵
      Schwarz A. Thousands of toddlers are medicated for A.D.H.D., report finds, raising worries. The New York Times, May 16, 2014
    65. ↵
      1. Friedman RA
      . Grief, depression, and the DSM-5. N Engl J Med. 2012;366(20):1855–1857pmid:22591292
      OpenUrlCrossRefPubMed
    66. ↵
      1. Ventola CL
      . Direct-to-consumer pharmaceutical advertising: therapeutic or toxic? P T. 2011;36(10):669–684
      OpenUrlPubMed
    67. ↵
      1. Mintzes B
      . Should patient groups accept money from drug companies? No. BMJ. 2007;334(7600):935pmid:17478846
      OpenUrlFREE Full Text
    68. ↵
      Harris G. Drug makers are advocacy group’s biggest donors. The New York Times, October 21, 2009
    69. ↵
      1. Schwartz LM,
      2. Woloshin S,
      3. Fowler FJ Jr,
      4. Welch HG
      . Enthusiasm for cancer screening in the United States. JAMA. 2004;291(1):71–78pmid:14709578
      OpenUrlCrossRefPubMed
    70. ↵
      1. Gates TJ
      . Screening for cancer: evaluating the evidence. Am Fam Physician. 2001;63(3):513–522pmid:11272300
      OpenUrlPubMed
    71. ↵
      American Academy of Pediatrics. Ten things physicians and patients should question. Available at: www.choosingwisely.org/doctor-patient-lists/american-academy-of-pediatrics/
    72. ↵
      1. Quinonez RA,
      2. Garber MD,
      3. Schroeder AR,
      4. et al.
      Choosing wisely in pediatric hospital medicine: five opportunities for improved healthcare value. J Hosp Med. 2013;8(9):479–485
      OpenUrlCrossRefPubMed
    73. ↵
      US Preventive Services Task Force. Section 3: topic work plan development. Available at: www.uspreventiveservicestaskforce.org/uspstf08/methods/procmanual3.htm
    74. ↵
      1. Wegwarth O,
      2. Gigerenzer G
      . Less is more: overdiagnosis and overtreatment: evaluation of what physicians tell their patients about screening harms. JAMA Intern Med. 2013;173(22):2086–2087pmid:24145597
      OpenUrlCrossRefPubMed
    75. ↵
      1. Stacey D,
      2. Légaré F,
      3. Col NF,
      4. et al
      . Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431pmid:24470076
      OpenUrlPubMed
    76. ↵
      1. Doust J
      . Diagnosis in general practice. Using probabilistic reasoning. BMJ. 2009;339:b3823pmid:19887528
      OpenUrlFREE Full Text
    77. ↵
      University of Colorado School of Medicine. Welcome to the Do No Harm Project. Available at: www.ucdenver.edu/academics/colleges/medicalschool/departments/medicine/GIM/education/DoNoHarmProject/Pages/Welcome.aspx
    78. ↵
      1. Batstra L,
      2. Frances A
      . Holding the line against diagnostic inflation in psychiatry. Psychother Psychosom. 2012;81(1):5–10pmid:22116200
      OpenUrlCrossRefPubMed
      1. Khoshoo V,
      2. Edell D
      . Previously healthy infants may have increased risk of aspiration during respiratory syncytial viral bronchiolitis. Pediatrics. 1999;104(6):1389–1390pmid:10585993
      OpenUrlAbstract/FREE Full Text
      1. Sheikh S,
      2. Allen E,
      3. Shell R,
      4. et al
      . Chronic aspiration without gastroesophageal reflux as a cause of chronic respiratory symptoms in neurologically normal infants. Chest. 2001;120(4):1190–1195pmid:11591559
      OpenUrlCrossRefPubMed
      1. Barnhart DC,
      2. Hall M,
      3. Mahant S,
      4. et al
      . Effectiveness of fundoplication at the time of gastrostomy in infants with neurological impairment. JAMA Pediatr. 2013;167(10):911–918pmid:23921627
      OpenUrlCrossRefPubMed
      1. Elder TE
      . The importance of relative standards in ADHD diagnoses: evidence based on exact birth dates. J Health Econ. 2010;29(5):641–656pmid:20638739
      OpenUrlCrossRefPubMed
      1. Morrow RL,
      2. Garland EJ,
      3. Wright JM,
      4. Maclure M,
      5. Taylor S,
      6. Dormuth CR
      . Influence of relative age on diagnosis and treatment of attention-deficit/hyperactivity disorder in children. CMAJ. 2012;184(7):755–762
      OpenUrlAbstract/FREE Full Text
      1. Frances A,
      2. Batstra L
      . Why so many epidemics of childhood mental disorder? J Dev Behav Pediatr. 2013;34(4):291–292pmid:23669874
      OpenUrlCrossRefPubMed
      1. Bogue CO,
      2. Murphy AJ,
      3. Gerstle JT,
      4. Moineddin R,
      5. Daneman A
      . Risk factors, complications, and outcomes of gallstones in children: a single-center review. J Pediatr Gastroenterol Nutr. 2010;50(3):303–308pmid:20118803
      OpenUrlCrossRefPubMed
      1. Sicherer SH,
      2. Wood RA,
      3. American Academy of Pediatrics Section on Allergy and Immunology
      . Allergy testing in childhood: using allergen-specific IgE tests. Pediatrics. 2012;129(1):193–197pmid:22201146
      OpenUrlAbstract/FREE Full Text
      1. Liu AH,
      2. Jaramillo R,
      3. Sicherer SH,
      4. et al.
      National prevalence and risk factors for food allergy and relationship to asthma: results from the National Health and Nutrition Examination Survey 2005–2006. J Allerg Clin Immunol. 2010;126(4):798–806.e713
      OpenUrlCrossRefPubMed
      1. Nelson SP,
      2. Chen EH,
      3. Syniar GM,
      4. Christoffel KK,
      5. Pediatric Practice Research Group
      . Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Arch Pediatr Adolesc Med. 1997;151(6):569–572pmid:9193240
      OpenUrlCrossRefPubMed
      1. Martin AJ,
      2. Pratt N,
      3. Kennedy JD,
      4. et al
      . Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics. 2002;109(6):1061–1067pmid:12042543
      OpenUrlAbstract/FREE Full Text
      1. Orenstein SR,
      2. Hassall E,
      3. Furmaga-Jablonska W,
      4. Atkinson S,
      5. Raanan M
      . Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(4):514–520.e514
      OpenUrlCrossRefPubMed
      1. Nelson SP,
      2. Kothari S,
      3. Wu EQ,
      4. Beaulieu N,
      5. McHale JM,
      6. Dabbous OH
      . Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy. J Med Econ. 2009;12(4):348–355pmid:19827992
      OpenUrlCrossRefPubMed
      1. Barron JJ,
      2. Tan H,
      3. Spalding J,
      4. Bakst AW,
      5. Singer J
      . Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr. 2007;45(4):421–427pmid:18030207
      OpenUrlCrossRefPubMed
      1. Kuzniewicz MW,
      2. Escobar GJ,
      3. Newman TB
      . Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics. 2009;124(4):1031–1039pmid:19786442
      OpenUrlAbstract/FREE Full Text
      1. Eggert LD,
      2. Wiedmeier SE,
      3. Wilson J,
      4. Christensen RD
      . The effect of instituting a prehospital-discharge newborn bilirubin screening program in an 18-hospital health system. Pediatrics. 2006;117(5). Available at: www.pediatrics.org/cgi/content/full/117/5/e855pmid:16651290
      OpenUrlAbstract/FREE Full Text
      1. Psaty BM,
      2. Rivara FP
      . Universal screening and drug treatment of dyslipidemia in children and adolescents. JAMA. 2012;307(3):257–258pmid:22174386
      OpenUrlCrossRefPubMed
      1. Gillman MW,
      2. Daniels SR
      . Is universal pediatric lipid screening justified? JAMA. 2012;307(3):259–260pmid:22253390
      OpenUrlCrossRefPubMed
      1. Newman TB,
      2. Pletcher MJ,
      3. Hulley SB
      . Overly aggressive new guidelines for lipid screening in children: evidence of a broken process. Pediatrics. 2012;130(2):349–352pmid:22826571
      OpenUrlFREE Full Text
      1. Schroeder AR,
      2. Redberg RF
      . Cholesterol screening and management in children and young adults should start early—NO! Clin Cardiol. 2012;35(11):665–668pmid:23161509
      OpenUrlCrossRefPubMed
      1. Shay DK,
      2. Holman RC,
      3. Newman RD,
      4. Liu LL,
      5. Stout JW,
      6. Anderson LJ
      . Bronchiolitis-associated hospitalizations among US children, 1980–1996. JAMA. 1999;282(15):1440–1446pmid:10535434
      OpenUrlCrossRefPubMed
      1. Mallory MD,
      2. Shay DK,
      3. Garrett J,
      4. Bordley WC
      . Bronchiolitis management preferences and the influence of pulse oximetry and respiratory rate on the decision to admit. Pediatrics. 2003;111(1). Available at: www.pediatrics.org/cgi/content/full/111/1/e45pmid:12509594
      OpenUrlAbstract/FREE Full Text
      1. Schroeder AR,
      2. Marmor AK,
      3. Pantell RH,
      4. Newman TB
      . Impact of pulse oximetry and oxygen therapy on length of stay in bronchiolitis hospitalizations. Arch Pediatr Adolesc Med. 2004;158(6):527–530pmid:15184214
      OpenUrlCrossRefPubMed
      1. Unger S,
      2. Cunningham S
      . Effect of oxygen supplementation on length of stay for infants hospitalized with acute viral bronchiolitis. Pediatrics. 2008;121(3):470–475pmid:18310194
      OpenUrlAbstract/FREE Full Text
      1. Andresen BS,
      2. Dobrowolski SF,
      3. O’Reilly L,
      4. et al
      . Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet. 2001;68(6):1408–1418pmid:11349232
      OpenUrlCrossRefPubMed
      1. Hero B,
      2. Simon T,
      3. Spitz R,
      4. et al
      . Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26(9):1504–1510pmid:18349403
      OpenUrlAbstract/FREE Full Text
      1. Marcus CL,
      2. Moore RH,
      3. Rosen CL,
      4. et al.,
      5. Childhood Adenotonsillectomy Trial (CHAT)
      . A randomized trial of adenotonsillectomy for childhood sleep apnea. N Engl J Med. 2013;368(25):2366–2376pmid:23692173
      OpenUrlCrossRefPubMed
      1. Goodman DC,
      2. Challener GJ
      . Tonsillectomy: a procedure in search of evidence. J Pediatr. 2012;160(5):716–718pmid:22336579
      OpenUrlCrossRefPubMed
      1. Erickson BK,
      2. Larson DR,
      3. St Sauver JL,
      4. Meverden RA,
      5. Orvidas LJ
      . Changes in incidence and indications of tonsillectomy and adenotonsillectomy, 1970–2005. Otolaryngol Head Neck Surg. 2009;140(6):894–901
      OpenUrlCrossRefPubMed
      1. Mannix R,
      2. Monuteaux MC,
      3. Schutzman SA,
      4. Meehan WP III,
      5. Nigrovic LE,
      6. Neuman MI
      . Isolated skull fractures: trends in management in US pediatric emergency departments. Ann Emerg Med. 2013;62(4):327–331pmid:23602429
      OpenUrlCrossRefPubMed
      1. Rollins MD,
      2. Barnhart DC,
      3. Greenberg RA,
      4. et al
      . Neurologically intact children with an isolated skull fracture may be safely discharged after brief observation. J Pediatr Surg. 2011;46(7):1342–1346pmid:21763832
      OpenUrlCrossRefPubMed
      1. Greenes DS,
      2. Schutzman SA
      . Infants with isolated skull fracture: what are their clinical characteristics, and do they require hospitalization? Ann Emerg Med. 1997;30(3):253–259pmid:9287884
      OpenUrlCrossRefPubMed
      1. Jodal U,
      2. Smellie JM,
      3. Lax H,
      4. Hoyer PF
      . Ten-year results of randomized treatment of children with severe vesicoureteral reflux. Final report of the International Reflux Study in Children. Pediatr Nephrol. 2006;21(6):785–792pmid:16565873
      OpenUrlCrossRefPubMed
      1. Hoberman A,
      2. Greenfield SP,
      3. Mattoo TK,
      4. et al.,
      5. RIVUR Trial Investigators
      . Antimicrobial prophylaxis for children with vesicoureteral reflux. N Engl J Med. 2014;370(25):2367–2376
      OpenUrlCrossRefPubMed
    • Copyright © 2014 by the American Academy of Pediatrics
    PreviousNext
    Back to top

    Advertising Disclaimer »

    In this issue

    Pediatrics
    Vol. 134, Issue 5
    1 Nov 2014
    • Table of Contents
    • Index by author
    View this article with LENS
    PreviousNext
    Email Article

    Thank you for your interest in spreading the word on American Academy of Pediatrics.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Overdiagnosis: How Our Compulsion for Diagnosis May Be Harming Children
    (Your Name) has sent you a message from American Academy of Pediatrics
    (Your Name) thought you would like to see the American Academy of Pediatrics web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Request Permissions
    Article Alerts
    Log in
    You will be redirected to aap.org to login or to create your account.
    Or Sign In to Email Alerts with your Email Address
    Citation Tools
    Overdiagnosis: How Our Compulsion for Diagnosis May Be Harming Children
    Eric R. Coon, Ricardo A. Quinonez, Virginia A. Moyer, Alan R. Schroeder
    Pediatrics Nov 2014, 134 (5) 1013-1023; DOI: 10.1542/peds.2014-1778

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Share
    Overdiagnosis: How Our Compulsion for Diagnosis May Be Harming Children
    Eric R. Coon, Ricardo A. Quinonez, Virginia A. Moyer, Alan R. Schroeder
    Pediatrics Nov 2014, 134 (5) 1013-1023; DOI: 10.1542/peds.2014-1778
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    Print
    Download PDF
    Insight Alerts
    • Table of Contents

    Jump to section

    • Article
      • Abstract
      • Research Methods to Investigate Overdiagnosis
      • Overdiagnosis in Children
      • How Is Overdiagnosis Harmful?
      • What Is Driving Overdiagnosis?
      • The Way Forward
      • Conclusions
      • Acknowledgments
      • Footnotes
      • References
    • Figures & Data
    • Info & Metrics
    • Comments

    Related Articles

    • No related articles found.
    • PubMed
    • Google Scholar

    Cited By...

    • Parental Perspectives on Continuous Pulse Oximetry Use in Bronchiolitis Hospitalizations
    • Covid-19: an opportunity to reduce unnecessary healthcare
    • Clinical Predictors for Abnormal Renal Bladder Ultrasound in Hospitalized Young Children With a First Febrile Urinary Tract Infection
    • Reducing Unnecessary Testing in Uncomplicated Skin and Soft Tissue Infections: A Quality Improvement Approach
    • Evidence of potential overdiagnosis and overtreatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents: protocol for a scoping review
    • A Mediastinal Mistake
    • A Framework for Evaluation of the Higher-Risk Infant After a Brief Resolved Unexplained Event
    • Development and Evaluation of High-Value Pediatrics: A High-Value Care Pediatric Resident Curriculum
    • Paediatric overdiagnosis modelled by coronary abnormality trends in Kawasaki disease
    • Overdiagnosis in primary care: framing the problem and finding solutions
    • Reducing Electrolyte Testing in Hospitalized Children by Using Quality Improvement Methods
    • Intermittent versus continuous oxygen saturation monitoring for infants hospitalised with bronchiolitis: study protocol for a pragmatic randomised controlled trial
    • Confronting the Hidden Curriculum of High-Value Care Education
    • We Can Teach How to Bend the Cost Curve: Lessons in Pediatric High-Value Health Care
    • Update on Pediatric Overuse
    • Infant Videofluoroscopic Swallow Study Testing, Swallowing Interventions, and Future Acute Respiratory Illness
    • Getting Burned by Lactic Acid
    • Oxygen Saturation and Bronchiolitis Severity
    • Industry Relationships With Pediatricians: Findings From the Open Payments Sunshine Act
    • Challenges and Limitations to Treating ADHD in Incarcerated Populations
    • Detection of abnormalities is not synonymous with patient benefit
    • Toward High-Value Care: A Quality Improvement Initiative to Reduce Unnecessary Repeat Complete Blood Counts and Basic Metabolic Panels on a Pediatric Hospitalist Service
    • Setting a research agenda for medical overuse
    • Impact of Physician Scorecards on Emergency Department Resource Use, Quality, and Efficiency
    • Lack of Clinical Utility of Urine Gram Stain for Suspected Urinary Tract Infection in Pediatric Patients
    • Google Scholar

    More in this TOC Section

    • Enrolling Minors in COVID-19 Vaccine Trials
    • Perspectives on Race and Medicine in the NICU
    • Islamic Beliefs About Milk Kinship and Donor Human Milk in the United States
    Show more Special Article

    Similar Articles

    Subjects

    • Public Health
      • Public Health
    • Medical Education
      • Medical Education

    Keywords

    • medical education
    • public health
    • Journal Info
    • Editorial Board
    • Editorial Policies
    • Overview
    • Licensing Information
    • Authors/Reviewers
    • Author Guidelines
    • Submit My Manuscript
    • Open Access
    • Reviewer Guidelines
    • Librarians
    • Institutional Subscriptions
    • Usage Stats
    • Support
    • Contact Us
    • Subscribe
    • Resources
    • Media Kit
    • About
    • International Access
    • Terms of Use
    • Privacy Statement
    • FAQ
    • AAP.org
    • shopAAP
    • Follow American Academy of Pediatrics on Instagram
    • Visit American Academy of Pediatrics on Facebook
    • Follow American Academy of Pediatrics on Twitter
    • Follow American Academy of Pediatrics on Youtube
    • RSS
    American Academy of Pediatrics

    © 2021 American Academy of Pediatrics